Maria Glymour, SD
Chair and Professor, Epidemiology - Boston University School of Public Health
Biography
Research Interests
- Alzheimer's disease and related causes of cognitive aging and dementia
- Modifiable determinants of dementia, including medications, behaviors, and socioeconomic position
- Health equity
- Social policies and health
- Causal inference in social epidemiology and dementia research
- Mentoring for excellence in public health
My research focuses on how social factors experienced across the lifecourse, from infancy to adulthood, influence cognitive function, dementia, stroke, and other health outcomes in old age. I am especially interested in education and other exposures amenable to policy interventions. The health of current cohorts of elderly individuals in the US reflect a lifetime of social exposures, including educational experiences shaped by major changes in schooling policies. Education is especially interesting because it is such a powerful predictor of health and historically, access to education has frequently been restricted based on race, gender, and other socially enforced criteria. One thread of my research examines how changes in schooling laws and school quality in the 20th century might have influenced the health and cognitive outcomes of current cohorts of elderly, including adults subject to race-based school segregation. Our results suggest that extra schooling has substantial benefits for memory function in the elderly. I have also worked on the influence of "place" on health, for example to understand the excess stroke burden for individuals who grew up in the US Stroke Belt. In a project with colleagues including Drs. Rachel Whitmer, Elizabeth Rose Mayeda, and Paola Gilsanz, we are continuing a unique multi-ethnic cohort of older adults in Northern California, with a wealth of lifecourse biological and social data to offer insight into the reasons for racial/ethnic differences in Alzheimer's and dementia risk (https://rachelwhitmer.ucdavis.edu/khandle).
A separate theme of my research focuses on overcoming methodological problems encountered in analyses of social determinants of health, Alzheimer's disease, and dementia. For many reasons, research focusing on lifecourse epidemiology as well as cognitive aging introduces substantial methodological challenges. Sometimes, these are conceptual challenges, and clear causal thinking can help! Many of these challenges are being addressed in the MELODEM (MEthods in LOngitudinal research on DEMentia) initiative, an international group of researchers focusing on analytic challenges in research on dementia and cognitive aging. MELODEM has working group phone calls on the first and third Thursdays of the month, open to all (https://sites.bu.edu/melodem/). My group works with numerous colleagues on methods to improve measurement, including crosswalking across data sets. For example, in work with Dr. Zeki Al Hazzouri, we are linking data sets with detailed information at different lifecourse periods -- e.g., childhood, early adulthood, and later adulthood -- to better evaluate long-term effects of exposures at specific sensitive ages. In work with Dr. Cathy Schaefer, Ron Krauss, and many others, we are fielding emulated trial designs in the large, diverse Kaiser Permanente Northern California cohort. This setting is exceptional for emulated trial designs because of the large size, long follow-up, and combination of high-quality clinical data plus social and genetic information for large groups of study participants.
I have advocated the use of causal directed acyclic graphs (DAGs) as a standard research tool to represent our causal hypotheses and help elucidate potential biases in proposed analyses. In other cases, the methodological problems require more analytical solutions that have been developed elsewhere in epidemiology or in other disciplines, but are rarely applied to these research questions. Instrumental variables analyses of natural or induced experiments are one promising example. Genetic variations have recently been advanced as possible instrumental variables to estimate the health effects of a wide range of phenotypes, an approach sometimes called “Mendelian Randomization.” Using genetic polymorphisms as instrumental variables could provide a very powerful tool for social epidemiology, but the inferences from such analyses rest on strong assumptions. Thus I am currently working with a team to explore approaches to evaluating the plausibility of those assumptions in applications for social epidemiology.
Students and post-doctoral fellows interested in research collaborations related to my work are welcome to send me an email directly or contact Marta Flores, mdflores@bu.edu, who handles my calendar. Feel free to reach out about the Epi Excellence (E2) Fellows or the Fellowship for Public Health Leveraging AI Responsibly (PHLAIR).
Education
- Harvard School of Public Health, SD Field of Study: Epidemiology
- Harvard School of Public Health, SM/ScM Field of Study: Epidemiology
- University of Chicago, AB Field of Study: Biology
Websites
Classes Taught
- SPHEP912
Publications
- Published on 10/16/2026
Colbeth HL, Posis AIB, Rizvi BM, Decarli CS, Glymour MM, George KM, Corrada MM, Gilsanz P, Whitmer RA. Role of APOE ?4 and ?2 With Longitudinal Cognitive Decline Among Those With Exceptional Longevity: The LifeAfter90 Study. Neurology. 2026 Nov 10; 107(9):e218596. PMID: 42886871.
Read At: PubMed
- Published on 10/15/2026
Nam GE, Liu J, Amin S, Romero KRF, Kunicki ZJ, Glymour MM, Casaletto K, Torres JM, Hayes-Larson E. Classification Matters: Divergent Estimates of Dementia Risk Factors in the Health and Retirement Study. Am J Epidemiol. 2026 Oct 15. PMID: 42878155.
Read At: PubMed
- Published on 9/24/2026
Meza E, Kapaon D, Tollman S, Glymour MM, Beltrán-Sánchez H, Bassil DT, Berkman LF. Intergenerational education and late-life cognitive performance: A comparison between rural Mexico and South Africa. Soc Sci Med. 2026 Sep 24; 410:119871. PMID: 42854270.
Read At: PubMed
- Published on 9/23/2026
Ferguson EL, Wang J, White JS, Possin K, Chodos A, Xia F, Raphael E, Smith AK, Glymour MM. Memantine, acetylcholinesterase inhibitors, and quality-of-care outcomes among patients with cognitive impairment: an emulated trial design. Alzheimers Dement (N Y). 2026; 12(3):e70306. PMID: 42781277.
Read At: PubMed
- Published on 9/15/2026
Hazzouri AZA, Sibai AM, Bassil D, Glymour MM, Manly JJ, Chahine MA, Chehabeddine L, Bekdache M, Elbejjani M. Late Life Learning, Cognition, and Aging: A Longitudinal study of middle and older-aged adults in Beirut, Lebanon (3LC study). medRxiv. 2026 Sep 15. PMID: 42780056.
Read At: PubMed
- Published on 9/8/2026
Wang J, Pederson AM, Flanders MD, Choi M, Buto P, Sims KD, Chen R, Couch E, Gilsanz P, Hayes KN, Zullo AR, Stokes A, Glymour MM, Ackley SF. Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes. medRxiv. 2026 Sep 08. PMID: 42818421.
Read At: PubMed
- Published on 9/3/2026
Jenson TE, Gause EL, Wang J, Ackley SF, Manly J, Fletcher E, Gilsanz P, Whitmer RA, Glymour MM, Jimenez MP. Depressive symptoms and neuroimaging markers of brain aging in an ethno-racially diverse sample: a Bayesian analysis. Am J Epidemiol. 2026 Sep 03; 195(9):2355-2363. PMID: 42299687.
Read At: PubMed
- Published on 9/1/2026
Pederson AM, Buto P, Zimmerman SC, Velez M, Sims KD, Murchland AR, Wang J, Glymour MM, Spartano NL, Weuve J, Gilsanz P, Chi F, Whitmer RA, Brennan AT. Clinical modifiers of the association between type 1 diabetes and dementia incidence. Alzheimers Dement. 2026 Sep; 22(9):e71799. PMID: 42764447.
Read At: PubMed
- Published on 8/25/2026
Kim MH, Colantonio LD, Glymour MM, Hamad R, Adler-Milstein J, Kershaw KN, Boscardin J, Wang Z, Oti AS, Howard VJ. Discordance Between Cognitive Impairment Status and Claims-Based ADRD Diagnosis: Temporal Patterns and Racial Differences in the REGARDS Cohort, 2006 to 2021. Alzheimer Dis Assoc Disord. 2026 Jul-Sep 01; 40(3):183-191. PMID: 42640625.
Read At: PubMed
- Published on 8/10/2026
Flores Romero KR, Gutierrez S, Zimmerman SC, Pederson AM, Thoma M, Chen R, Kotwal A, Glymour M, Casaletto K, Torres JM. Social isolation, loneliness, and blood-based AD/ADRD biomarkers in a nationally-representative study of middle-aged and older adults. medRxiv. 2026 Aug 10. PMID: 42845496.
Read At: PubMed
View 572 more publications:View Full Profile at BUMC
News & In the Media
- Published on August 6, 2026
- Published on June 4, 2026
- Published on April 2, 2026
-
Published on March 20, 2026
New Estimates of Uncounted COVID-19 Deaths Reveal Critical Gaps in US Death Investigation System
-
Published on March 13, 2026
Hackathon for Health Equity Sparks Student Interest in Epidemiology
- Published on November 21, 2025
-
Published on September 28, 2025
I’m Against Medical Research Cuts. We Need Those Answers for Our Health
-
Published on July 17, 2025
Texas Flood Should Not Have Happened. What Went Wrong? | Opinion
-
Published on June 14, 2025
Rise in Mortality Rates Linked to Heart Disease and Diabetes Among Less Educated Americans
-
Published on June 12, 2025
Congress Is Moving Backward on Funding for Alzheimer’s Disease Research | Opinion
- Published on February 15, 2025
- Published on January 9, 2025
- Published on December 13, 2024
-
Published on December 7, 2024
A Caregiving Chasm: Professor Reflects on the Shortcomings of the US Healthcare System
-
Published on November 13, 2024
Public Health Master’s Degrees in Epidemiology: What Questions to Ask
- Published on October 11, 2024
-
Published on October 8, 2024
Innovative Approaches to Prevent Dementia Funded by $28.8 Million Federal Grant
-
Published on September 27, 2024
Professor Receives $29M NIH Grant to Study Dementia Risk Factors, Prevention, and Treatment
-
Published on April 12, 2024
Depression May Lead to Faster Cognitive Decline among Black, Latino Adults
- Published on November 9, 2023
-
Published on October 6, 2023
Both High and Low HDL Cholesterol Tied to Increased Risk of Dementia
- Published on October 5, 2023
-
Published on September 8, 2023
After 2020 Increase, Excess Mortality among People with Dementia Drops in Year 2 of COVID
- Published on August 31, 2023
-
Published on July 10, 2023
FDA Gives Full Approval for New Alzheimer’s Drug, but Will It Help Black Patients?
-
Published on July 7, 2023
Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
-
Published on July 6, 2023
Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients